acetylcysteine has been researched along with Glioblastoma with Sarcomatous Component in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dan, S; Guo, WZ; Ohashi, Y; Shiina, I; Uetake, S; Umeda, E; Wang, Y; Watanabe, C; Yamori, T | 1 |
| Brem, H; DiMeco, F; Fiorindi, A; Gaini, SM; Legnani, FG; Olivi, A; Pradilla, G; Recinos, PF; Thai, QA; Tyler, BM | 1 |
2 other study(ies) available for acetylcysteine and Glioblastoma with Sarcomatous Component
| Article | Year |
|---|---|
Ridaifen-SB8, a novel tamoxifen derivative, induces apoptosis via reactive oxygen species-dependent signaling pathway.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Caspases; Cell Line, Tumor; Estrogen Receptor alpha; Free Radical Scavengers; Gene Knockdown Techniques; Gliosarcoma; Humans; MCF-7 Cells; Membrane Potential, Mitochondrial; Protein Transport; Reactive Oxygen Species; Signal Transduction; Tamoxifen | 2013 |
Lactacystin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Implants; Female; Glioma; Gliosarcoma; Infusions, Intralesional; Neoplasms, Experimental; Polymers; Rats; Rats, Inbred F344 | 2006 |